Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Contact Research Centre

Cytomegalovirus immunisation

Not recruiting

Registered drug

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Finland

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Sodium Chloride

Contact Research Centre

Meningococcal infection

Not recruiting

Registered drugNo placebo

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo

Finland

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide

Contact Research Centre

Influenza immunisation

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)

Contact Research Centre

Respiratory syncytial virus infection

Not recruiting

Investigational

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational

Finland

Participants:0–17 years · Healthy volunteers
Substances:534

Contact Research Centre

Meningococcal immunisation

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo

Finland

Participants:0–17 years · Healthy volunteers
Substances:TETANUS TOXOID

Contact Research Centre

Meningococcal immunisation

Not recruiting

Registered drugNo placebo

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo

Finland

Participants:0–17 years · Healthy volunteers
Substances:RNMB1

Contact Research Centre

Find therapies in clinical trials near you

20 trials match your criteria

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Metapneumovirus infection

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Pneumococcal immunisation

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Influenza+1

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Pneumococcal immunisation

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Respiratory syncytial virus infection+3

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Cytomegalovirus immunisation

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Meningococcal infection

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Influenza immunisation

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Respiratory syncytial virus infection

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Meningococcal immunisation

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Meningococcal immunisation

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.